Press Releases

INOVIO to Report Fourth Quarter and Year-End 2021 Financial Results on March 1, 2022

Posted on February 15, 2022

INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18

Posted on December 14, 2021

INOVIO Announces Strategy to Address Omicron (B.1.1.529) and Future SARS-CoV-2 Variants

Posted on November 30, 2021

INOVIO Collaborates with GuardRX and Geneva University Hospitals for Heterologous Booster Clinical Trial of its Ebola DNA Vaccine Candidate, INO-4201

Posted on November 16, 2021

INOVIO to Give Eight Presentations at the 34th International Papillomavirus Conference

Posted on November 15, 2021

INOVIO Reports Third Quarter 2021 Financial Results

Posted on November 9, 2021

INOVIO Receives U.S. FDA Authorization to Proceed with INNOVATE Phase 3 Segment for its COVID-19 Vaccine Candidate, INO-4800, in the U.S.

Posted on November 9, 2021

INOVIO Expands Executive Leadership to Prepare for Commercial Operations

Posted on November 5, 2021

INOVIO Further Expands INNOVATE Phase 3 Trial for COVID-19 DNA Vaccine Candidate INO-4800 With Regulatory Authorization from India

Posted on November 3, 2021

INOVIO to Report Third Quarter 2021 Financial Results on November 9, 2021

Posted on October 27, 2021

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.